Table 4.

Reported venous thromboembolic events for second dose BNT162b2 vaccine

Time-period post vaccination	Number of events	Number of person-days	Incidence rate ratio (95% confidence intervals)
Venous thromboembolic events
Baselinea	1830	593,391	1.00
Clearanceb	86	32,022	0.75 (0.60–0.93)
0–6 days	37	16,351	0.64 (0.46–0.89)
7–13 days	42	16,305	0.74 (0.54–1.00)
14–20 days	57	16,252	1.00 (0.77–1.31)
21–27 days	46	16,164	0.83 (0.62–1.12)
0–27 days	182	65,072	0.80 (0.69–0.94)
Cerebral venous sinus thrombosis
Baselinea	≤5	1548	1.00
Clearanceb	≤5	84	3.95 (0.37–42.26)
0–6 days	0	42	0.00 (NA)
7–13 days	0	42	0.00 (NA)
14–20 days	0	42	0.00 (NA)
21–27 days	0	42	0.00 (NA)
0–27 days	0	168	0.00 (NA)
Deep vein thrombosis
Baselinea	736	244,086	1.00
Clearanceb	43	13,178	0.90 (0.66–1.23)
0–6 days	17	6698	0.70 (0.43–1.13)
7–13 days	15	6685	0.62 (0.37–1.03)
14–20 days	20	6660	0.83 (0.53–1.30)
21–27 days	19	6615	0.81 (0.51–1.28)
0–27 days	71	26,658	0.74 (0.57–0.95)

NA Not Applicable as when there are 0 events, the CI cannot be calculated using conditional Poisson regression.

^aIncludes all three baseline periods before dose 1 and before and after dose 2—see Fig. 1.

^bSecond dose clearance period. NB ≤5 Denotes minimum allowable reported value.